Galmed Pharmaceuticals Ltd. (GLMD)
NASDAQ: GLMD · Real-Time Price · USD
3.825
-0.055 (-1.42%)
At close: Sep 8, 2026, 4:00 PM EDT
3.700
-0.125 (-3.27%)
After-hours: Sep 8, 2026, 4:51 PM EDT
Galmed Pharmaceuticals Employees
As of December 31, 2025, Galmed Pharmaceuticals had 6 total employees, including 3 full-time and 3 part-time employees. The number of employees did not change compared to the previous year.
Employees
6
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$1,890,500
Market Cap
3.83M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 6 | 0 | - | 3 | 3 |
| Dec 31, 2024 | 6 | -2 | -25.00% | 3 | 3 |
| Dec 31, 2023 | 8 | -2 | -20.00% | 3 | 5 |
| Dec 31, 2022 | 10 | -14 | -58.33% | 4 | 6 |
| Dec 31, 2021 | 24 | 0 | - | 19 | 5 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| PMGC Holdings | 34 |
| Calidi Biotherapeutics | 29 |
| GeoVax Labs | 19 |
| VivoSim Labs | 15 |
| BioRestorative Therapies | 14 |
| Revelation Biosciences | 9 |
| Mustang Bio | 4 |
| Silo Pharma | 3 |
GLMD News
- 20 days ago - Colospan completes feasibility study of new assesment platform - TheFly
- 20 days ago - Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology - PRNewsWire
- 21 days ago - Galmed trading halted, news pending - TheFly
- 22 days ago - Galmed reports results from study of a combination of Aramchol and Xtandi - TheFly
- 22 days ago - Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI®) Alone in Prostate Cancer Models - PRNewsWire
- 6 weeks ago - Galmed’s Aramchol ODF formulation shows positive results in Parkinson’s - TheFly
- 6 weeks ago - Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market - PRNewsWire
- 7 weeks ago - Galmed announces development of novel LNP cardiac targeted Aramchol formulation - TheFly